Showing results (81-90 of 236) with videos related to
Sort By:
Pageof 24
Cureus|September 10, 2019
Clinical Characteristics of Hydralazine-induced LupusHoma Timlin, Michael Wu, Monica Crespo-Bosque, et al.Clinical Rheumatology|May 1, 2019
Uncommon presentations in ANCA vasculitis: clinical characteristics and outcomesVeena S Katikineni, Sam Kant, Eric J Gapud, et al.Best Practice & Research. Clinical Rheumatology|March 20, 2013
Vasculitis in the intensive care unitErin M Wilfong, Philip SeoThe American Journal of Medicine|June 24, 2004
The antineutrophil cytoplasmic antibody-associated vasculitidesPhilip Seo, John H StoneCurrent Opinion in Rheumatology|December 17, 2008
Advances in the use of biologic agents for the treatment of systemic vasculitisSharon A Chung, Philip SeoRheumatic Diseases Clinics of North America|August 7, 2010
Microscopic polyangiitisSharon A Chung, Philip SeoInternational Journal of Clinical Rheumatology|June 21, 2013
Biologic agents in systemic vasculitisCharles F Henderson, Philip SeoLupus|January 2, 2024
COVID vaccine-induced lupus nephritis: Case report and review of the literatureAntonio Salas, Ayotola Fatola, Rebecca Krimins, et al.RMD Open|October 6, 2025
Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamideDuvuru Geetha, Thomas Neumann, Alexandre Karras, et al.Journal of the American Society of Nephrology : JASN|November 9, 2014
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvementDuvuru Geetha, Ulrich Specks, John H Stone, et al.Pageof 24